EKSO - Ekso Bionics Holdings Inc Stock Price, Fair Value and News

1.39USD+0.10 (+7.75%)Market Closed

Market Summary

USD1.39+0.10

Market Closed

7.75%

EKSO Stock Price

View Fullscreen

EKSO RSI Chart

EKSO Valuation

Market Cap

24.9M

Price/Earnings (Trailing)

-1.64

Price/Sales (Trailing)

1.36

Price/Free Cashflow

-2.04

EKSO Price/Sales (Trailing)

EKSO Profitability

Return on Equity

-120.56%

Return on Assets

-52.56%

Free Cashflow Yield

-49.07%

EKSO Fundamentals

EKSO Revenue

Revenue (TTM)

18.3M

Rev. Growth (Yr)

33.93%

Rev. Growth (Qtr)

5.21%

EKSO Earnings

Earnings (TTM)

-15.2M

Earnings Growth (Yr)

-1.13%

Earnings Growth (Qtr)

4.49%

Breaking Down EKSO Revenue

Last 7 days

-2.1%

Last 30 days

-1.4%

Last 90 days

-16.8%

Trailing 12 Months

-13.7%

How does EKSO drawdown profile look like?

EKSO Financial Health

Current Ratio

2.49

EKSO Investor Care

Shares Dilution (1Y)

8.31%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	14.4M	15.8M	17.1M	18.3M
2022	11.9M	13.0M	13.3M	12.8M
2021	8.2M	8.1M	8.3M	11.2M
2020	11.8M	10.8M	10.3M	7.8M
2019	12.4M	12.7M	13.5M	13.9M
2018	8.4M	9.5M	10.5M	11.3M
2017	7.2M	7.5M	7.5M	7.4M
2016	15.5M	14.9M	13.6M	14.2M
2015	6.0M	6.9M	8.2M	8.7M
2014	3.7M	3.9M	4.6M	5.3M
2013	3.4M	4.4M	5.2M	3.3M
2012	0	0	0	2.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Ekso Bionics Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 22, 2024	wong jerome	acquired	-	-	7,474	chief financial officer
Mar 22, 2024	jones jason c	acquired	-	-	7,474	chief operating officer
Nov 02, 2023	lathan corinna	bought	5,004	1.2412	4,032	-
Aug 23, 2023	lathan corinna	bought	5,221	0.9494	5,500	-
Aug 17, 2023	davis scott g.	sold	-37,281	0.9956	-37,446	president & coo
Aug 17, 2023	wong jerome	sold	-12,727	0.9956	-12,784	chief financial officer
Aug 10, 2023	lathan corinna	bought	5,251	1.25	4,201	-
Jun 12, 2023	wong jerome	acquired	-	-	170,068	chief financial officer
Jun 12, 2023	jones jason c	acquired	-	-	10,800	chief operating officer
Jun 12, 2023	wong jerome	acquired	-	-	8,200	chief financial officer

Which funds bought or sold EKSO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	772,046	1,092,310	-%
Mar 08, 2024	ICA Group Wealth Management, LLC	new	-	373	373	-%
Feb 20, 2024	VOISARD ASSET MANAGEMENT GROUP, INC.	new	-	10.00	10.00	-%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	added	4,375	889	895	-%
Feb 15, 2024	Front Row Advisors LLC	unchanged	-	55.00	78.00	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-47.57	-	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	reduced	-86.11	-16,713	15,043	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-11,002	-	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	sold off	-100	-14,774	-	-%
Feb 14, 2024	Kent Lake Capital LLC	new	-	352,895	352,895	0.14%

Are Funds Buying or Selling EKSO?

Are funds buying EKSO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EKSO

No. of Funds

Unveiling Ekso Bionics Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 11, 2022	azimut investments s.a.	3.34%	423,000	SC 13G/A
Feb 12, 2021	azimut investments s.a.	086%	423,000	SC 13G
Nov 12, 2020	puissance cross-border opportunities ii llc	0.36%	29,828	SC 13D/A
Jun 18, 2020	armistice capital, llc	4.99%	398,692	SC 13G
Jun 16, 2020	intracoastal capital, llc	4.99%	387,369	SC 13G
Mar 05, 2020	puissance cross-border opportunities ii llc	13.3%	11,616,000	SC 13D/A
Dec 27, 2019	armistice capital, llc	4.99%	4,356,559	SC 13G

Recent SEC filings of Ekso Bionics Holdings Inc

View All Filings

Date Filed	Form Type	Document
Apr 04, 2024	4/A	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Mar 18, 2024	S-8	Employee Benefits Plan
Mar 18, 2024	11-K	Employee Benefit Details
Mar 14, 2024	4	Insider Trading
Mar 04, 2024	8-K	Current Report
Mar 04, 2024	10-K	Annual Report
Jan 16, 2024	8-K	Current Report
Jan 12, 2024	424B5	Prospectus Filed

Peers (Alternatives to Ekso Bionics Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	189.3B	40.1B	-9.21%	5.29%	33.08	4.72	-8.12%	-17.45%
BDX	67.9B	19.5B	-1.55%	-8.27%	54.08	3.48	4.02%	-22.04%
ALGN	23.7B	3.9B	-1.72%	-7.67%	53.19	6.13	3.42%	23.09%
BAX	20.5B	14.8B	-5.55%	-6.65%	7.71	1.38	2.12%	209.17%
MID-CAP
HSIC	9.1B	12.3B	-5.72%	-13.98%	21.94	0.74	-2.44%	-22.68%
ATR	9.1B	3.5B	-2.81%	14.53%	31.84	2.6	4.97%	18.89%
BIO	8.8B	2.7B	-10.75%	-38.18%	-13.76	3.28	-4.68%	82.43%
XRAY	6.5B	4.0B	-8.29%	-23.99%	-48.26	1.64	1.10%	85.84%
AXNX	3.4B	366.4M	-0.38%	19.00%	-567.94	9.41	33.86%	89.83%
PDCO	2.3B	6.6B	-5.95%	-4.86%	11.79	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-4.92%	-19.00%	-1.93	0.41	7.73%	-1066.14%
ANIK	372.1M	166.7M	-1.34%	-7.94%	-4.5	2.23	6.67%	-456.34%
ANGO	255.5M	324.0M	14.75%	-32.34%	-1.33	0.79	-3.19%	-337.41%
APYX	49.2M	52.3M	-18.86%	-53.44%	-2.63	0.94	17.61%	19.28%
AEMD	4.0M	3.7M	-9.04%	297.37%	-0.32	1.06	5.77%	8.23%

Ekso Bionics Holdings Inc News

Latest updates

Ekso Bionics Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	5.2%	4,847,000	4,607,000	4,703,000	4,122,000	3,619,000	3,329,000	3,329,000	2,567,000	4,076,000	3,049,000	2,211,000	1,910,000	1,126,500	2,897,000	2,264,000	1,468,000	3,720,000	3,319,000	3,262,000	3,616,000	3,296,500
Gross Profit	-3.5%	2,369,000	2,456,000	2,254,000	2,000,000	1,678,000	1,686,000	1,641,000	1,209,000	2,415,000	1,807,000	1,292,000	1,235,000	1,361,000	1,813,000	1,259,000	637,000	1,855,000	1,750,000	1,560,000	1,599,000	1,491,000
Operating Expenses	8.0%	5,818,000	5,387,000	6,538,000	6,448,000	6,114,000	5,340,000	4,870,000	5,446,000	6,967,000	4,596,000	4,640,000	4,374,000	4,358,000	4,234,000	4,351,000	5,418,000	4,694,000	5,540,000	6,658,000	6,511,000	6,629,500
S&GA Expenses	-3.4%	1,983,000	2,052,000	2,349,000	2,088,000	1,945,000	1,742,000	1,841,000	1,629,000	2,040,000	1,685,000	1,787,000	1,793,000	1,780,000	1,740,000	1,712,000	2,520,000	2,732,000	2,818,000	3,039,000	2,809,000	2,935,000
R&D Expenses	13.3%	1,313,500	1,159,000	1,398,000	1,154,000	945,500	887,000	873,000	921,000	619,000	618,000	709,000	603,000	712,000	599,000	452,000	711,000	564,000	1,149,000	1,499,000	1,384,000	1,368,000
EBITDA Margin	-	-	-	-	-	-	-	-0.66	-0.75	-0.81	-	-	-1.68	-1.76	-1.15	-1.10	-1.00	-0.84	-1.96	-2.07	-2.12	-
Interest Expenses	-9.4%	58,000	64,000	61,000	127,000	66,000	34,000	29,000	27,000	36,000	24,000	27,000	26,000	26,000	23,000	38,000	52,000	68,000	88,000	107,000	121,000	131,500
Income Taxes	-100.0%	-	1,000	-	-	112,000	10,000	-	-	104,000	-	-	-	103,000	6,000	-3,000	3,000	301,000	-	8,000	-	457,000
EBT Margin	-	-	-	-	-	-	-	-0.74	-0.82	-0.87	-	-	-1.70	-1.78	-1.17	-1.13	-1.03	-0.87	-2.00	-2.12	-2.17	-
Net Income	4.5%	-3,214,000	-3,365,000	-4,230,000	-4,389,000	-3,178,000	-4,304,000	-2,978,000	-4,620,000	-2,863,000	-1,958,000	-1,273,000	-3,670,000	-3,976,000	2,452,000	-11,767,000	-2,534,000	-2,721,000	206,000	-3,066,000	-6,551,000	-4,132,000
Net Income Margin	6.5%	-0.83	-0.89	-1.02	-1.03	-1.17	-1.11	-0.95	-0.90	-0.87	-1.31	-0.79	-2.07	-	-	-	-	-	-	-	-	-
Free Cashflow	51.7%	-1,627,000	-3,370,000	-2,958,000	-4,256,000	-3,697,000	-2,731,000	-4,248,000	-4,206,000	-3,074,000	-2,475,000	-3,606,000	-2,000,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-7.3%	29.00	31.00	34.00	37.00	41.00	39.00	41.00	44.00	49.00	51.00	53.00	57.00	21.00	23.00	22.00	17.00	22.00	20.00	26.00	21.00	18.00
Current Assets	-9.6%	20.00	22.00	25.00	28.00	31.00	37.00	39.00	43.00	48.00	49.00	51.00	55.00	18.00	22.00	20.00	14.00	19.00	17.00	22.00	17.00	15.00
Cash Equivalents	-13.1%	9.00	10.00	13.00	16.00	21.00	29.00	32.00	36.00	40.00	43.00	46.00	50.00	13.00	15.00	13.00	9.00	11.00	8.00	13.00	9.00	8.00
Inventory	-8.0%	5.00	5.00	6.00	6.00	5.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	4.00	3.00	3.00
Net PPE	-3.3%	2.00	2.00	2.00	2.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00
Goodwill	0%	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	2.4%	16.00	16.00	16.00	16.00	15.00	11.00	9.00	11.00	12.00	12.00	13.00	16.00	16.00	15.00	22.00	12.00	15.00	14.00	20.00	16.00	15.00
Current Liabilities	3.6%	8.00	8.00	10.00	10.00	9.00	8.00	5.00	6.00	7.00	5.00	5.00	6.00	5.00	5.00	7.00	8.00	8.00	8.00	9.00	10.00	10.00
Shareholder's Equity	-17.4%	13.00	15.00	18.00	21.00	25.00	29.00	32.00	33.00	37.00	39.00	40.00	41.00	4.00	8.00	-	5.00	7.00	6.00	5.00	5.00	3.00
Retained Earnings	-1.4%	-239	-235	-232	-228	-223	-220	-216	-213	-208	-206	-204	-202	-199	-195	-197	-185	-183	-180	-180	-177	-171
Additional Paid-In Capital	0.5%	252	250	250	249	249	248	247	247	246	245	245	244	204	204	198	191	190	187	186	182	174
Shares Outstanding	4.3%	15.00	14.00	14.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	11.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	19.00	-	-	-	64.00	-	-	-	52.00	-	-	-	68.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	52.8%	-1,584	-3,353	-2,903	-4,214	-3,644	-2,590	-4,248	-4,206	-3,075	-2,475	-3,606	-2,000	-1,740	-1,270	-4,023	-1,722	-1,495	-4,569	-4,531	-5,177	-5,154
Share Based Compensation	8.6%	479	441	514	424	928	537	582	499	791	663	519	356	798	517	508	587	575	487	557	636	636
Cashflow From Investing	-152.9%	-43.00	-17.00	-55.00	-42.00	-5,034	-141	-	-	1.00	-	-	-	-	-	-	-	-	-	-53.00	-7.00	-80.00
Cashflow From Financing	-	-	-	-	-	-	-	-	-	-	-	-	38,712	-	2,544	8,749	-589	4,269	-598	8,599	6,769	-104

EKSO Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 18,279	$ 12,912
Cost of revenue	9,200	6,698
Gross profit	9,079	6,214
Operating expenses:
Sales and marketing	8,472	7,157
Research and development	5,025	3,626
General and administrative	10,694	10,987
Total operating expenses	24,191	21,770
Loss from operations	(15,112)	(15,556)
Other (expense) income, net:
Interest expense, net	(302)	(156)
(Loss) gain on revaluation of warrant liabilities	(133)	1,317
Unrealized gain (loss) on foreign exchange	412	(655)
Other expense, net	(63)	(30)
Total other (expense) income, net	(86)	476
Net loss	(15,198)	(15,080)
Foreign currency translation adjustments	(407)	580
Comprehensive loss	$ (15,605)	$ (14,500)
Net loss per share applicable to common shareholders, basic and diluted (in dollars per share)	$ (1.1)	$ (1.16)
Weighted average number of shares outstanding, basic and diluted (in shares)	13,867	12,962

EKSO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and restricted cash	$ 8,638	$ 20,525
Accounts receivable, net of allowances of $79 and $40, respectively	5,645	4,625
Inventories	5,050	5,187
Prepaid expenses and other current assets	875	700
Total current assets	20,208	31,037
Property and equipment, net	2,018	2,680
Right-of-use assets	977	1,307
Intangible assets, net	4,892	5,217
Goodwill	431	431
Other assets	392	231
Total assets	28,918	40,903
Current liabilities:
Accounts payable	1,847	3,151
Accrued liabilities	2,664	2,278
Deferred revenues, current	1,993	1,121
Notes payable, current	1,250	2,310
Lease liabilities, current	363	341
Total current liabilities	8,117	9,201
Deferred revenues	2,169	1,032
Notes payable, net	4,832	3,767
Lease liabilities	723	1,087
Warrant liabilities	366	233
Other non-current liabilities	105	141
Total liabilities	16,312	15,461
Commitments and contingencies (Note 16)
Stockholders' equity:
Convertible preferred stock, $0.001 par value; 10,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.001 par value; 141,429 shares authorized; 14,848 and 13,203 shares issued and outstanding as of December 31, 2023 and 2022, respectively	15	13
Additional paid-in capital	251,580	248,813
Accumulated other comprehensive income	156	563
Accumulated deficit	(239,145)	(223,947)
Total stockholders' equity	12,606	25,442
Total liabilities and stockholders' equity	$ 28,918	$ 40,903

About Ekso Bionics Holdings Inc

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therap, an adjustable and lower-limb powered exoskeleton; and Ekso Indego Personal, a powered lower limb orthosis. It has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in San Rafael, California.

CEO	Mr. Scott G. Davis
WEBSITE	eksobionics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	72

Ekso Bionics Holdings Inc Frequently Asked Questions

What is the ticker symbol for Ekso Bionics Holdings Inc? What does EKSO stand for in stocks?

EKSO is the stock ticker symbol of Ekso Bionics Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ekso Bionics Holdings Inc (EKSO)?

As of Fri Apr 12 2024, market cap of Ekso Bionics Holdings Inc is 24.89 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EKSO stock?

You can check EKSO's fair value in chart for subscribers.

What is the fair value of EKSO stock?

You can check EKSO's fair value in chart for subscribers. The fair value of Ekso Bionics Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ekso Bionics Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EKSO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ekso Bionics Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether EKSO is over valued or under valued. Whether Ekso Bionics Holdings Inc is cheap or expensive depends on the assumptions which impact Ekso Bionics Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EKSO.

What is Ekso Bionics Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, EKSO's PE ratio (Price to Earnings) is -1.64 and Price to Sales (PS) ratio is 1.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EKSO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ekso Bionics Holdings Inc's stock?

In the past 10 years, Ekso Bionics Holdings Inc has provided -0.249 (multiply by 100 for percentage) rate of return.